Mark D. Tolpin MD
HIV/AIDS Medicine, Healthcare Associated Infections, Transplant/Immunocompromised States
Consultant (semiretired) global clinical/regulatory drug/device development:
Join to View Full Profile
256 Glen AveMillburn, NJ 07041
Phone+1 973-379-5589
Fax+1 973-379-5312
Dr. Tolpin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Infectious Diseases, 1977 - 1979
Drexel University College of MedicineResidency, Pediatrics, 1975 - 1977
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1974
Certifications & Licensure
NJ State Medical License 1987 - 2019
American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 84 citationsOral terbinafine in the treatment of toenail onychomycosis: North American multicenter trialLynn A. Drake, Neil H. Shear, Jon P. Arlette, Richard Cloutier, Frederick W. Danbye
Journal of the American Academy of Dermatology. 1997-11-01 - 136 citationsGenetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant p...Gerald McMahon, Paul H. Ehrlich, Zeinab A. Moustafa, Linda A. McCarthy, Diane Dottavio
Hepatology. 1992-05-01 - 27 citationsHuman monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication.Mostafa Nokta, Mark D. Tolpin, Paul I. Nadler, Richard B. Pollard
Antiviral Research. 1991-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
